Product Information
LITHIUM CARBONATE 300 MG CAP is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.1039 per EA under NDC 31722054510. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Sep 25, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722054510
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LITHIUM CARBONATEApproval Type
Generic (ANDA)
FDA Application
ANDA090702FDA Approved
9/25/2009
TE Code
AB
On Market Since
12/15/2009
Pharmacological Classes
Price Statistics
The NADAC for LITHIUM CARBONATE 300 MG CAP has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 252.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1039 per EA |
|---|---|
| All-time high | $0.1240 (Mar 13, 2024) |
| All-time low | $0.0276 (Nov 18, 2015) |
| 52-week high | $0.1151 |
| 52-week low | $0.0926 |
| Median price | $0.0488 |
| Average price | $0.0568 |
| Largest weekly change | +43.9% (Aug 23, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lithium carbonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LITHIUM CARBONATE 300 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for LITHIUM CARBONATE 300 MG CAP, manufactured by Camber Pharmaceuticals Inc., is $0.1039 per EA (NDC 31722054510), effective Sep 30, 2026.
How has the price of LITHIUM CARBONATE 300 MG CAP changed over time?
Over the history we have for it, the NADAC for LITHIUM CARBONATE 300 MG CAP has risen 252.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LITHIUM CARBONATE 300 MG CAP?
Since Nov 28, 2013, the NADAC for LITHIUM CARBONATE 300 MG CAP has ranged from a low of $0.0276 (Nov 18, 2015) to a high of $0.1240 (Mar 13, 2024), with a median of $0.0488 per EA.
Are there cheaper alternatives to LITHIUM CARBONATE 300 MG CAP?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as LITHIUM CARBONATE 300 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures LITHIUM CARBONATE 300 MG CAP?
LITHIUM CARBONATE 300 MG CAP (NDC 31722054510) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.